Molecular Diagnostics — Canine Cancer

Molecular Diagnostics — Canine Cancer

Antech is committed to molecular diagnostics and the detection of canine cancer. Our innovative diagnostic solutions, coupled with our dynamic partnerships, allow us to offer impactful options to help diagnose and treat canine cancer.   

OncoK9® by PetDx — An aid in cancer detection test using a simple blood draw

Antech has partnered with PetDx to offer OncoK9 — a multi-cancer detection (MCD) test that detects and characterizes cancer-associated genomic alterations in DNA isolated from canine whole blood samples, or liquid biopsy, using next-generation sequencing (NGS) technology.

OncoK9 detects 30 types of canine cancer, including the most common lymphoma, hemangiosarcoma, soft tissue sarcoma, mast cell tumor, osteosarcoma, mammary gland carcinoma, anal sac adenocarcinoma, and malignant melanoma.

Discover why OncoK9 is a next-generation DNA sequencing panel 

CADET® BRAF — Early detection of urinary tract cancer for improved outcomes

CADET BRAF evaluates urine samples from dogs for the presence of cells containing a mutation for canine bladder/prostate cancer (TCC/UC). It’s cutting-edge technology that is accurate, affordable, and convenient for both veterinarian and pet owner. 

All this test requires is a small urine sample. 

Uncover the power of molecular diagnostics 

SearchLight DNA® by Vidium Animal Health® — A canine cancer genomic test for clearer, faster treatment options

SearchLight DNA™ identifies mutations in canine cancer genes and provides insights into a cancer’s origin, its behavior, and the optimal approach to treatment. It incorporates advanced diagnostic, prognostic, and predictive biomarkers to provide greater clarity about the behavior of a canine’s tumor. 

  • Finds mutations in the DNA of dog’s cancer cells 
  • Identifies chemo-sensitivity gene MDR1 
  • Checks for 120 relevant cancer genes 
  • Appropriate for cytology and histology samples 
  • Precision diagnostic, prognostic and therapeutic indicator 

You can target specific tumor mutations and treat with greater confidence.